Date: 2015-12-21
Type of information: Nomination
Compound:
Company: Swedish Orphan Biovitrum - SOBI (Sweden)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 21, 2015, Swedish Orphan Biovitrum (Sobi) announced that Lars Dreiøe has been appointed Senior Vice President Chief Quality & Compliance Officer. Lars Dreiøe joins Sobi from global pharmaceutical company ALK in Denmark where he has been International Head of Quality. Lars brings 20 years of experience in the Biotech and Pharmaceutical industry in the Quality, Manufacturing, Product Safety and Regulatory Affairs areas. He will join Sobi on 18 January 2016.
Financial terms:
Latest news:
